CRVS
Corvus Pharmaceuticals Inc
NASDAQ: CRVS · HEALTHCARE · BIOTECHNOLOGY
$10.62
-7.41% today
Updated 2026-11-12
Market cap
$843.73M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.62
Dividend yield
—
52W range
$6 – $27
Volume
1.1M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.5
Quality
B3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-4.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →259 stocks currently score above 75
Price targets
Analyst target
$31.50
+196.61%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -4.30 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-12.28M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Net income | $-41.31M | $-27.03M | $-62.29M | $-15.28M | $-20.34M |
| EPS | — | — | — | — | $-0.62 |
| Free cash flow | $-27.29M | $-23.97M | $-25.42M | $-32.97M | $-12.28M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-11 | VAN, DEN BROEK RICHARD | Buy | 15,000 | — |
| 2026-06-11 | THOMPSON, PETER A. | Buy | 15,000 | — |
| 2026-06-11 | MOORE, DAVID SCOTT | Buy | 15,000 | — |
Peer comparison
Smart narrative
Corvus Pharmaceuticals Inc trades at $10.62. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -4.30, it sits in the distress.
Frequently asked questions
What is Corvus Pharmaceuticals Inc's stock price?
Corvus Pharmaceuticals Inc (CRVS) trades at $10.62.
Is Corvus Pharmaceuticals Inc overvalued?
Corvus Pharmaceuticals Inc carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Corvus Pharmaceuticals Inc (CRVS)?
The 12-month analyst consensus target is $31.50, about 196.6% above the current $10.62. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Corvus Pharmaceuticals Inc's Altman Z-Score is -4.30, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-30.87%
Beta1.43
50D MA$11.94
200D MA$14.44
Shares out0.08B
Float0.07B
Short ratio—
Avg volume1.1M
Performance
1 week+7.22%
1 month+0.19%
3 months-28.45%
YTD+36.88%
1 year+33.25%
3 years—
5 years—